Asia-Pacific Plasma Therapy Market to be worth $214 Million by 2030

Asia-Pacific Plasma Therapy Market, By Type (Pure Platelet-rich Plasma, Platelet-rich Fibrin), Application (Orthopedics, Dermatology, Cosmetology, Rheumatology, Ophthalmology, Stomatology), End User (Hospitals & Clinics, Research Institutes) - Forecast to 2030

Meticulous Research^®, a leading global market research company, published a research report titled, ‘Asia-Pacific Plasma Therapy Market, By Type (Pure Platelet-rich Plasma, Platelet-rich Fibrin), Application (Orthopedics, Dermatology, Cosmetology, Rheumatology, Ophthalmology, Stomatology), End User (Hospitals & Clinics, Research Institutes) - Forecast to 2030’.

According to this latest publication from Meticulous Research^®, the Asia-Pacific Plasma Therapy Market is expected to reach $214 million by 2030 at a CAGR of 13.4% from 2023 to 2030. The growth of the Asia-Pacific plasma therapy market is attributed to the significant rise in healthcare expenditure, the growing geriatric population, and the significant number of accidents in the region. In addition, the conferences promoting the use of platelet-rich Plasma (PRP) and research activities with PRP therapy are further expected to drive the growth of the market in Asia-Pacific. However, the stringent regulatory framework for PRP use is the major challenge in this market. Increasing applications of PRP treatments and advancements in healthcare infrastructure in Asia-Pacific countries provide market growth opportunities.

Key Players

The key players operating in the Asia-Pacific plasma therapy market are Arthrex, Inc. (U.S.) DePuy Synthesis, Inc. (Johnson & Johnson) (U.S.), Global Stem Cells Group, Inc.(U.S.), Terumo Corporation (Japan), Regen Lab SA (Switzerland), Stryker Corporation (U.S.) Zimmer Biomet Holdings, Inc. (U.S.), Exactech Inc. (U.S.), Beijing Manson Technology Co., Ltd. (China), Alocuro (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A.(Spain), Octapharma AG (Switzerland), and CSL Limited (Australia).

Asia-Pacific Plasma Therapy Market: Future Outlook

The Asia-Pacific plasma therapy market is segmented by type (Pure PRP, Leukocyte-rich PRP, Pure Platelet-rich Fibrin, and Leukocyte and Platelet-rich Fibrin), application (Orthopedics & Traumatology, Rheumatology, Dermatology & Cosmetology, Ophthalmology, Stomatology & Odontology, and Other Applications), end user (Hospitals & Clinics & Research Institutes) and country. The study also evaluates industry competitors and analyzes their market share at the country level.

Among all types studied in this report, in 2023, the pure PRP segment is expected to have the largest market share. Pure PRP is one of the preferred methods as it is a point-of-care therapy in the place of surgery or other invasive methods, primarily contributing to the largest share of the segment. Additionally, increasing application of pure PRP, such as treating torn tendons, tendinitis, muscle injuries, arthritis-related pain, joint injuries, hair loss, and others, contributes to the segment's largest share.

Among all applications studied in this report, the dermatology & cosmetology segment is expected to register the highest CAGR over the forecast period. The high incidence of skin and hair-related conditions, the increased popularity worldwide concerning looking good, and lucrative facial features are the major driving factors for the segment. Additionally, the high incidence of dermatological problems and the advantages of PRP therapy in dermatology is expected to drive the segmental growth of the market.

Among all end users studied in this report, in 2023, the hospitals & clinics segment is expected to have the largest market share. Hospitals and clinics use platelet-rich plasma (PRP) therapy for pain management, regenerative medicines, joint & bone surgeries, cosmetic enhancements, hair growth, and sports injuries. PRP treatments are mostly applied to manage accidents and trauma, infectious diseases, orthopedic treatments, cosmetics, dermatology, and hair growth & transplant, contributing to the largest segment share.

Geographic Review

This research report analyzes major countries and comprehensively analyzes China, Japan, India, South Korea, Australia, Singapore, and the Rest of Asia-Pacific. In 2023, Japan is expected to account for the largest share of the Asia-Pacific plasma therapy market. The country's large market share is attributed to the growing awareness about PRP therapy, the rising number of road accidents, the growing preference for cosmetic procedures, and increasing infertility. For instance, many people in the country are affected by infertility. The World Bank reported that the country's fertility rate in 2019 was 1.4 births per woman, which declined to 1.3 births per woman in 2021. Physicians involved in in-vitro fertilization (IVF) use PRP to promote endometrial growth and improve pregnancy chances. The decline in the fertility rate and the adoption of PRP in infertility is expected to drive the market demand in the country.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5556

Key questions answered in the report-

Which are the high-growth market segments in terms of type, application, end user, and country?
What was the historical market for plasma therapy market in Asia-Pacific?
What are the market forecasts and estimates for 2023–2030?
What are the major drivers, restraints, challenges, and opportunities in the Asia-Pacific plasma therapy market?
Who are the major players in the Asia-Pacific plasma therapy market?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research